Form 4: Cargo Therapeutics Chief Medical Officer, Ginna Laport, Reports Acquisition of 50,000 Shares of Common Stock

Ginna Laport, Chief Medical Officer of CARGO Therapeutics, reports acquiring 50,000 shares of common stock through restricted stock units (RSUs).

Summary

• Ginna Laport, the Chief Medical Officer of CARGO Therapeutics, Inc. (CRGX), filed a Form 4 on March 18, 2025.
• The report details a transaction on March 14, 2025, where Ms. Laport acquired 50,000 shares of common stock.
• These shares were acquired through restricted stock units (RSUs) at a price of $0.
• The RSUs vest in installments, with 1/16th vesting quarterly starting January 1, 2025, and full vesting occurring on the fourth anniversary of this date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by a key executive is generally a good sign, but it's a routine transaction related to compensation.

Positives

• The acquisition of shares by a key executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting schedule of the RSUs suggests a long-term commitment from the Chief Medical Officer to the company's success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the compensation structure for key executives at CARGO Therapeutics.

Stakeholder Impact

• The acquisition of shares by a key executive could positively influence investor sentiment.

Key Dates